A look at Exact Sciences Corporation’s acquisition by Abbott: review EXAS revenue growth, margins, and CRC/MRD screening ...

Abbott is acquiring Exact Sciences for $23 billion, the global healthcare leader announced on Thursday. Exact Sciences shareholders will receive $105 per common share, totaling approximately $21 ...

Exact Sciences is selling off a slice of the prostate cancer precision testing business it obtained through its $2.8 billion takeover of Genomic Health. MDxHealth is paying $25 million in cash upfront ...

With new features like an onboard high-resolution camera, integrated scanning wheels, and software connectivity, this device is going to be a game-changer for printers, converters, and ink suppliers.

The rumors are now a reality. Abbott Laboratories is acquiring Exact Sciences for $21 billion, marking what could be the biggest medtech deal of 2025. The deal’s announcement comes less than 24 hours ...

If you have been wondering whether Exact Sciences is still worth buying after its huge run, you are not alone. This breakdown is designed to help you decide if the current price makes sense. The stock ...

Exact Sciences is adding early cancer detection to its pipeline through its buyout of Thrive Earlier Detection for up to $2.15 billion in cash and stock. The deal comes just three months after Thrive ...

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Abbott has agreed to acquire cancer test-maker Exact ...

Exact Sciences is an oncology diagnostics company that has a strong position in stool-based DNA testing for colorectal cancer. The cancer diagnostics market is large, and growing, but blood-based ...

As Halloween approaches, Exact Sciences is warding off a particularly terrifying occurrence: skipping colorectal cancer screening. A newly launched campaign touts the company’s Cologuard test as a non ...